Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania

Revista Brasileira de Psiquiatria

Volumn 36, Issue 1, 2014, Pages 39-46

  Stertz, Laura ^a,b   Fries, Gabriel Rodrigo ^a,b   de Aguiar, Bianca Wollenhaupt ^a,b   Pfaffenseller, Bianca ^a,b   Valvassori, Samira S ^b   Gubert, Carolina ^a,b   Ferreira, Camila L ^b   Moretti, Morgana ^b   Ceresér, Keila M ^a,b   Kauer Sant'Anna, Márcia ^a,b   Quevedo, João ^b   Kapczinski, Flavio ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

BDNF; Bipolar disorder; Histone deacetylase; Mood stabilizer; Sodium butyrate

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HISTONE DEACETYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; EXPERIMENTAL HYPERACTIVITY; LOCOMOTION; MALE; MANIA; MOOD DISORDER; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN FIELD TEST; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; BUTYRIC ACID; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; HISTONE DEACETYLASES; LITHIUM; MALE; MOTOR ACTIVITY; PREFRONTAL CORTEX; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; VALPROIC ACID;

EID: 84894764070     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2013-1094     Document Type: Article

References (42)

1. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol. 2008;11:1123-34.
2. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci. 2006;7:583-90.
3. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8:355-67.
4. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074-80.
5. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734-41.
6. Bordonaro M, Lazarova DL, Sartorelli AC. The activation of betacatenin by Wnt signaling mediates the effects of histone deacetylase inhibitors. Exp Cell Res. 2007;313:1652-66.
7. Kuipers SD, Bramham CR. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel. 2006;9:580-6.
8. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig. 2010;7:243-50.
9. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398:215-9.
10. Tramontina JF, Andreazza AC, Kauer-Sant'anna M, Stertz L, Goi J, Chiarani F, et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett. 2009;452:111-3.
11. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry. 2009;14:51-9.
12. Frey BN, Andreazza AC, Cereser KM, Martins MR, Valvassori SS, Reus GZ, et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci. 2006;79:281-6.
13. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science. 2003;302:890-3.
14. Fukuchi M, Nii T, Ishimaru N, Minamino A, Hara D, Takasaki I, et al. Valproic acid induces up-or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions. Neurosci Res. 2009;65:35-43.
15. Kwon B, Houpt TA. Phospho-acetylation of histone H3 in the amygdala after acute lithium chloride. Brain Res. 2010;1333:36-47.
16. Yamawaki Y, Fuchikami M, Morinobu S, Segawa M, Matsumoto T, Yamawaki S. Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J Biol Psychiatry. 2012;13:458-67.
17. Schroeder FA, Lin CL, Crusio WE, Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry. 2007;62:55-64.
18. Moretti M, Valvassori SS, Varela RB, Ferreira CL, Rochi N, Benedet J, et al. Behavioral and neurochemical effects of sodium butyrate in an animal model of mania. Behav Pharmacol. 2011;22:766-72.
19. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:209-24.
20. de Lima MN, Presti-Torres J, Vedana G, Alcalde LA, Stertz L, Fries GR, et al. Early life stress decreases hippocampal BDNF content and exacerbates recognition memory deficits induced by repeated Damphetamine exposure. Behav Brain Res. 2012;224:100-6.
21. Pinheiro RM, de Lima MN, Fries GR, Garcia VA, Presti-Torres J, Hallmenschlager LH, et al. Early life stress exacerbates cognitive dysfunction induced by d-amphetamine: amelioration by valproic acid. J Neural Transm. 2012;119:627-37.
22. Brambilla P, Stanley JA, Nicoletti MA, Sassi RB, Mallinger AG, Frank E, et al. 1H magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in bipolar disorder patients. J Affect Disord. 2005;86:61-7.
23. Yurgelun-Todd DA, Ross AJ. Functional magnetic resonance imaging studies in bipolar disorder. CNS Spectr. 2006;11:287-97.
24. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. San Diego: Academic Press; 1986.
25. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977;83:346-56.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 2001;25:402-8.
27. Liu JC, Baker RE, Chow W, Sun CK, Elsholtz HP. Epigenetic mechanisms in the dopamine D2 receptor-dependent inhibition of the prolactin gene. Mol Endocrinol. 2005;19:1904-17.
28. Romieu P, Host L, Gobaille S, Sandner G, Aunis D, Zwiller J. Histone deacetylase inhibitors decrease cocaine but not sucrose selfadministration in rats. J Neurosci. 2008;28:9342-8.
29. Arent CO, Valvassori SS, Fries GR, Stertz L, Ferreira CL, Lopes-Borges J, et al. Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors. Mol Neurobiol. 2011;43:207-14.
30. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737-49.
31. Grayson DR, Kundakovic M, Sharma RP. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol. 2010;77:126-35.
32. Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, et al. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res. 2010;44:263-70.
33. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2010;35:870-80.
34. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER, et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/-mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron. 2004;42:947-59.
35. Covington HE 3rd, Vialou VF, Laplant Q, Ohnishi YN, Nestler EJ. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett. 2011;493:122-6.
36. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003;23:9418-27.
37. Levenson JM, O'Riordan KJ, Brown KD, Trinh MA, Molfese DL, Sweatt JD. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem. 2004;279:40545-59.
38. Dencker D, Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res. 2010;207:78-83.
39. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther. 2007;321:892-901.
40. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res. 2007;85:525-35.
41. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45:156-61.
42. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl). 2001;158:100-6.